Edition:
United States

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

233.84USD
23 Feb 2018
Change (% chg)

$7.10 (+3.13%)
Prev Close
$226.74
Open
$228.50
Day's High
$233.92
Day's Low
$226.70
Volume
222,597
Avg. Vol
344,332
52-wk High
$248.81
52-wk Low
$158.12

Select another date:

Tue, Jan 30 2018

BRIEF-Illumina Q4 GAAP Earnings Per Share $0.46

* ILLUMINA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2017

BRIEF-Illumina Awarded $26.7 Mln In Patent Suit Against Ariosa Diagnostics

* ILLUMINA AWARDED $26.7M IN PATENT SUIT AGAINST ARIOSA DIAGNOSTICS, INC.

Illumina wins $26.7 million in patent fight with Roche unit Ariosa

Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

UPDATE 1-Illumina wins $26.7 mln in patent fight with Roche unit Ariosa

Jan 25 Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

Illumina wins $26.7 million in patent fight with Roche unit Ariosa

Jan 25 Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.

BRIEF-Premaitha Health Says Secured Right To Appeal First Instance Judgment

* HAS SECURED RIGHT TO APPEAL A FIRST INSTANCE JUDGMENT IN ITS ONGOING LITIGATION WITH ILLUMINA INC. AND OTHERS

Cornell must arbitrate claims it was duped into Illumina patent deal: judge

A federal magistrate judge on Friday ruled Cornell University must arbitrate its claim that a former co-plaintiff duped it into settling a gene-sequencing patent dispute with Illumina Inc.

BRIEF-Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018

* ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018

BRIEF-HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement

* HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT

Select another date: